How Baxter International Makes Money

Baxter International operates an essential, high-volume hospital consumable and medical capital equipment business model: (1) Intravenous Fluids & Drug Delivery Consumables (~35% of revenue / ~$5.1B), manufacturing billions of flexible VIAFLEX plastic bags containing normal saline, dextrose, lactated Ringer's, and premixed IV medications delivered daily to hospitals worldwide; (2) Connected Hospital Systems & Hillrom Furniture (~21% of revenue / ~$3.1B), selling Centrella smart hospital beds, Progressa ICU therapy beds, and integrated surgical tables with continuous patient weight and fall-prevention sensors; (3) Specialty Injectable Pharmaceuticals (~16% of revenue / ~$2.4B), monetizing volatile inhaled general anesthetics (Sevoflurane, Desflurane) and critical care injectable drugs; (4) Front Line Diagnostic Care (~9% of revenue / ~$1.3B), manufacturing Welch Allyn blood pressure monitors, otoscopes, and physical diagnostic instruments; and (5) Advanced Surgery Biosurgery (~8% of revenue / ~$1.2B), supplying FLOSEAL gelatin-thrombin hemostatic matrices that arrest active surgical bleeding in operating rooms. Baxter generates gross margins near 42% and over $1.7 billion in operating cash flow.

Under CEO José Almeida, Baxter is executing four key growth initiatives: (1) Accelerating Novum IQ Smart Infusion Platform Placements: Commercializing the next-generation Novum IQ large-volume and syringe infusion pump ecosystem, featuring Dose IQ safety software and automated EMR interoperability; (2) Expanding Connected Hospital & Smart Bed Penetration: Integrating Centrella smart hospital beds with Voicera communication badges and hospital EMRs to automate continuous clinical surveillance; (3) Expanding Biosurgery & Specialty Injectables: Accelerating international sales of FLOSEAL and TISSEEL surgical sealants across outpatient surgical centers; and (4) Portfolio Simplification & Operational Margin Expansion: Realizing post-separation cost synergies following the Vantive kidney care carve-out to expand adjusted operating margins toward 18%.